Osteoarthritis of the knee
Conditions
Interventions
Implementation of exercise therapy (rehabilitation) at home.
Sponsors
Tanabe Hideki
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients who meet the following criteria (1) to (8) will be eligible: (1) Outpatients aged 50 to under 80 years who complain of knee joint pain. Both male and female patients are eligible. (2) Patients who have received sufficient explanation using an information document, understood its content, and have provided written consent to participate in the clinical trial voluntarily. (3) Patients who are new to the medical institution. Previous visits are allowed, but patients should not have received treatment within the past 4 weeks. (4) The presence of asymmetry in symptoms is acceptable, but the side with more severe symptoms will be the target. The following should be confirmed, and the patient must meet at least one of the criteria: Morning stiffness lasting under 30 minutes Joint crepitus Tenderness at the joint line Bone thickening (osteophyte formation) No warmth in the joint (5) Patients whose radiographic examination (X-ray) during screening shows Kellgren-Lawrence grade II or higher. (6) Patients whose VAS (Visual Analog Scale) score during screening is 6.0 or lower and who are able to perform rehabilitation exercises. (7) Patients who agree not to use over-the-counter pain medications (topical or oral) other than those prescribed by the principal investigator during the clinical trial. (8) Patients who regularly use a smartphone and are capable of operating the application.
Exclusion criteria
Exclusion criteria: (1) Patients who received treatment for the knee joint at another medical institution within 4 weeks prior to obtaining consent, that is, patients who underwent exercise therapy or intra-articular injection in the knee within 4 weeks prior to obtaining consent. (2) Patients who have undergone or are scheduled to undergo surgical treatment of the knee within 6 months prior to obtaining consent. (3) Patients with pain in the affected area who are unable to perform rehabilitation exercises. (4) Patients requiring intra-articular injection of medication in the knee joint. (5) Patients requiring joint fluid aspiration. (6) Patients with conditions requiring continuous or intermittent administration of steroids. (7) Patients with a history of joint cartilage damage or destruction due to obvious trauma or pyogenic arthritis. (8) Patients diagnosed with rheumatoid arthritis, gout, pseudogout, or collagen disease. (9) Patients with severe heart failure. (10) Patients with severe liver dysfunction. (11) Patients with severe renal dysfunction.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change from baseline at 12 weeks in JKOM (overall evaluation) (Test product app group vs. standard treatment group) | — |
Contacts
Public ContactKikuno Dakeshita
CrossMed Co.,Ltd.
Outcome results
None listed